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Abstract: There is an urgent need for new ways to treat Alzheimer’s disease (AD), the most common cause of dementia 
in the elderly. Current therapies are modestly effective at treating the symptoms, and do not significantly alter the course 
of the disease. Over the years, a range of epidemiological and experimental studies have demonstrated interactions   
between diabetes mellitus and AD. As both diseases are leading causes of morbidity and mortality in the elderly and are 
frequent co-morbid conditions, it has raised the possibility that treating diabetes might be effective in slowing AD. This is 
currently being attempted with drugs such as the insulin sensitizer rosiglitazone. These two diseases share many clinical 
and biochemical features, such as elevated oxidative stress, vascular dysfunction, amyloidogenesis and impaired glucose 
metabolism suggesting common pathogenic mechanisms. The main thrust of this review will be to explore the evidence 
from a pathological point of view to determine whether diabetes can cause or exacerbate AD. This was supported by  
a number of animal models of AD that have been shown to have enhanced pathology when diabetic conditions were  
induced. The one drawback in linking diabetes and insulin to AD has been the postmortem studies of diabetic brains  
demonstrating that AD pathology was not increased; in fact decreased pathology has often been reported. In addition,  
diabetes induces its own distinct features of neuropathology different from AD. There are common pathological features 
to be considered including vascular abnormalities, a major feature arising from diabetes; there is increasing evidence that 
vascular abnormalities can contribute to AD. The most important common mechanism between insulin-resistant (type II) 
diabetes and AD could be impaired insulin signaling; a form of toxic amyloid can damage neuronal insulin receptors and 
affect insulin signaling and cell survival. It has even been suggested that AD could be considered as “type 3 diabetes” 
since insulin can be produced in brain. Another common feature of diabetes and AD are increased advanced glycation 
endproduct-modified proteins are found in diabetes and in the AD brain; the receptor for advanced glycation endproducts 
plays a prominent role in both diseases. In addition, a major role for insulin degrading enzyme in the degradation of A 
peptide has been identified. Although clinical trials of certain types of diabetic medications for treatment of AD have been 
conducted, further understanding the common pathological processes of diabetes and AD are needed to determine whether 
these diseases share common therapeutic targets. 
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1. INTRODUCTION 
  Alzheimer’s disease (AD) is the most common cause of 
dementia in the elderly resulting in significant morbidity and 
health care costs. Depending on populations being studied, 
the incidence of AD is 10% in those over 65 years of old, 
rising to 50% in those over 85 years of age. By the middle of 
this century, as the population progressively ages, AD is 
becoming an epidemic that will affect 13.2 to 16 million in 
the United States [1, 2]. Current approved therapies involve 
the use of acetycholinesterase (AChE) inhibitors that target 
the symptoms of AD and do little to affect disease progres-
sion [3]. Many pathological processes are involved in AD 
pathology. As this disease can take 15-25 years to manifest 
as overt cognitive decline, many of these processes are oc-
curring in the brain and periphery simultaneously. Taking   
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into account 25 years of research on AD, it can be concluded 
that AD results in an accumulation of misfolded proteins, 
which results in oxidative stress, inflammation and which is 
contributed to by these factors, leading to mitochondrial 
damage and synaptic dysfunction. AD is a disease of synap-
tic failure particularly in the hippocampus. 
  Although the majority of research in AD has focused on 
the amyloid beta (A) peptide and how it is generated and 
metabolized, the role of insulin, glucose regulation and dia-
betes has been a constant area of research. Glucose metabo-
lism has a pivotal role in maintaining all aspects of the health 
of the brain; glucose dysregulation has a multitude of patho-
logical effects with many of these being observed in patients 
with diabetes. It has been known for many years that reduced 
glucose metabolism, as demonstrated by positron emission 
tomography using Fluorodeoxyglucose as ligand, is an early 
indication of the development of AD [4-6]. The significance 
of these scans is that as changes can be identified before   
significant neuronal loss, the reduced glucose metabolism is 
a strong indication of insulin signaling defects in brain being 694    Current Neuropharmacology, 2011, Vol. 9, No. 4  Arab et al. 
an early pathological event. In addition, intranasal admini-
stration of insulin to ensure cerebral rather than peripheral 
uptake is an effective method of enhancing cognition, both in 
animal models and now AD patients [7]. The major mystery 
is that the brains of diabetics do not have enhanced AD pa-
thology [8] so the link between cause of insulin deficiency 
and AD is still unclear. 
  Insulin is the major hormone that regulates glucose me-
tabolism in the periphery and the brain, so it can be expected 
that diseases with glucose dysregulation, namely Type I and 
Type II diabetes, will also have consequences on brain func-
tion. There has been a large body of basic scientific and epi-
demiological studies showing how diabetes can accelerate 
AD. Based on these findings one might expect that treating 
diabetes will slow down or reverse AD neuropathological 
changes. There have been many excellent reviews over the 
last 5 years that make this case in a compelling manner; 
however the aim of this review is to consider this question 
from a human pathological point of view. Why are there   
not enhanced AD pathological changes in the brains of   
elderly with diabetes? Does this mean the two diseases have 
no interrelationship or are the pathological mechanisms of 
diabetes and AD only sharing some of the features? We   
will examine many of the common features of diabetes and 
AD to determine how they might interact and also address 
the issue of using diabetic medication and/or insulin as AD 
therapy. 
  In Fig. (1), a simplified scheme of the interaction be-
tween insulin deficiency/resistance (not necessarily diabetes) 
is proposed. As we will examine, some of the features of how 
failure of insulin signaling leads to AD pathology has been 
better elucidated in animal models rather than in humans. 
1.1. Glucose Metabolism as a Biomarker for AD 
  Positron emission tomography (PET) using radiolabeled 
fluorodeoxyglucose (FDG) has become one of the oldest and 
most accurate biomarker tools for identification of mild cog-
nitive impairment (MCI) and early stage AD in living sub-
jects [9-12]. Results show that there is significant regional 
cerebral glucose hypometabolism early in the disease. These 
findings have been replicated over approximately the last 20 
years and are now being validated using new amyloid imag-
ing ligands [13]. FDG-PET measurements have been shown 
to correlate well with transition form MCI to AD, and with 
biochemical biomarkers of early AD, including CSF A and 
tau levels [14-17]. As these changes in glucose metabolism 
are occurring early in the disease, it can be suggested that 
these changes are likely due to defects in insulin signaling, 
not due to neuronal cell loss. One study showed that struc-
tural gray matter alterations were detectable in mild AD in 
amygdala and hippocampus, while changes in glucose me-
tabolism were occurring in posterior cingulated gyrus and 
parietal lobes [18]. It was shown in a volunteer population 
using FDG-PET that administration of insulin resulted in 
significant enhanced cortical glucose metabolism [19]. This 
effect was least in cerebellum, a brain region not signifi-
cantly affected in AD. Reduced FDG-PET uptake was   
observed in a population with mild hyperglycemia; the   
reduction in glucose metabolism was in similar brain regions 
affected by AD [20].  
1.2. Diabetes and AD 
  Diabetics develop a diverse range of pathological condi-
tions, both in brain and periphery, due to the consequences 
of glucose dysregulation; as many of the pathologies share 
features with AD or putative AD processes, research has 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Potential periphery to brain links between type 1 and type 2 diabetes and Alzheimer’s disease. Peripheral insulin deficiency or 
insulin resistance leading to hyperglycemia, increased deposition of advanced glycation endproduct (AGE) modified proteins in the vascula-
ture and increased vascular inflammation. These events lead to reduced transport of insulin across the blood brain barrier to the brain.  
Reduced neuronal insulin receptor signaling, due to insulin deficiency or insulin receptor desensitization alter a number of cellular signaling 
pathways that can promote amyloid beta (A) formation, phosphorylation of tau and reduced glucose uptake and metabolism by neurons. Consequences of Aberrant Insulin Regulation in the Brain  Current Neuropharmacology, 2011, Vol. 9, No. 4    695 
hypothesized that diabetes (Type I or Type II) is a risk factor 
for AD. Insulin, a polypeptide hormone consisting of a 21 
amino acid  chain and a 30 amino acid  chain, plays the 
central role in regulating energy metabolism in the body. 
Diabetes as the “sugar” disease has been identified for centu-
ries, but it has been shown that insulin has numerous neu-
rotrophic, metabolic and endocrine functions in the brain, 
being centrally involved in memory and neuronal survival 
(reviewed in [21,22]). This hormone is mainly produced by 
the beta cells of the Islets of Langerhans of the pancreas, but 
expression of insulin mRNA in brain has been detected [23]. 
Type-1 diabetes (T1D) develops when insulin synthesis de-
clines after the Islet cells are lost, potentially due to autoim-
mune causes or viral infections. T1D, also called insulin-
dependent diabetes, is treated by administration of insulin 
through injection. Without these injections, this disease is 
invariably fatal due to the subject not being able to maintain 
adequate glucose levels.  
1.3. AD and Type-2 Diabetes 
  Type-2 diabetes (T2D) also referred to as insulin-
resistant diabetes or non-insulin dependent diabetes, tends to 
be an age-related disease frequently associated with obesity, 
smoking, and failure to exercise, and characterized by en-
dogenous insulin resistance. Subjects have hyperinsulinemia, 
hyperglycemia, glucose intolerance, atherosclerosis, hyper-
tension and adiposity [24], which are all risk factors for AD. 
The cause of T2D is not fully understood, but a range of ex-
perimental studies have associated insulin resistance with 
reduced levels of insulin receptor expression, reduced insulin 
receptor kinase activation and reduced activation of insulin 
receptor substrate (IRS)-1 and downstream signaling, and 
increased expression of inflammatory associated proteins 
[25-28]. 
  Clinical studies have examined the shared risk for AD 
and T2D. It has been observed that 81% of AD patients had 
either T2D or impaired fasting glucose levels [29]. These 
studies raised an interesting question whether AD patients 
were predisposed to T2D, or if T2D accelerated AD. It has 
been consistently observed in epidemiological studies that 
diabetes, particularly T2D, is associated with cognitive de-
cline; these studies are the foundation of the hypothesis that 
diabetes could be accelerating pathological processes in AD 
[30-33]. The potential role of insulin and/or diabetes in pre-
cipitating or accelerating AD has been reviewed extensively 
(representative examples [21, 30, 34-39]). Many have taken 
the position that there is a positive association between dia-
betes or insulin signaling deficits and AD based on epidemi-
ological data as well as animal or cellular models. However, 
it is our supposition that the data have been unclear and con-
flicting, and now is not supported by neuropathological ex-
amination of brains from AD patients with diabetes [40]. If 
diabetes does not lead to increased AD pathology, one could 
suggest that diabetic medications will not be effective in 
slowing AD pathology [41]. 
2. FEATURES OF AD AND INSULIN DEFICIENCY 
  AD is the most common cause of dementia in the elderly 
whose incidence is increasing as the population is becoming 
older. The disease manifests as short-term memory loss that 
progresses in severity to global dementia. Usually the cogni-
tive decline in AD is associated with the progressive devel-
opment of extracellular senile plaques, which consist of fi-
brillar aggregates of amyloid- (A) deposits, and intracellu-
lar neurofibrillary tangles (NFT), composed of hyperphos-
phorylated tau protein located in the cortex and hippocampus 
of the affected brain; the disruption of synaptic function; and 
cerebral atrophy. The central issue for understanding the 
interaction of diabetes and AD has been to determine if and 
how diabetes/insulin deficiency can accelerate these above 
listed pathological features. This has brought up a number of 
potential mechanisms, including the interaction of insulin 
degrading enzyme (IDE) in AD and diabetes [42-44]; the 
involvement of advanced glycation endproduct-modified 
proteins and the receptor for advanced glycation endproducts 
(RAGE) [45-47], the interference of A with insulin receptor 
signaling [39,48-52]; and the role of insulin sensitizers in 
neuroprotection [53,54]. 
2.1. Insulin and Insulin Growth Factor in the Brain 
  Insulin and insulin-like growth factor (IGF) have been 
proven to have vital roles in the brain. They control the neu-
ronal functions by directing the metabolic, neurotrophic, 
neuromodulatory and neuroendocrine actions that are neces-
sary elements for learning and establishing memory [34]. 
Studies showed that IGF receptors are widely distributed on 
neurons and astrocytes [55, 56], and insulin receptors (IR) 
are expressed in the cerebral vasculature and can mediate the 
transport of insulin across the blood brain barrier (BBB) 
[56]. Insulin and IGF immunoreactivity has been observed in 
human brain, and can be localized to neuronal structures by 
immunocytochemistry [57]. This could still arise due to neu-
ronal uptake of insulin transported into the brain. However, 
insulin, IGF-I and IGF -II mRNA have been detected in hu-
man brain samples indicating cerebral synthesis occurs. Lev-
els of insulin mRNA were significantly lower in AD samples 
compared to matched control samples; however, the expres-
sion of insulin growth factors (IGF-I or IGF-II) and insulin 
receptor (IR) mRNA levels were similar between AD and 
control samples. By comparison, earlier studies using immu-
nohistochemistry showed increased insulin and insulin re-
ceptor immunoreactivity in AD and Parkinson’s disease (PD) 
tissue sections [57-59]. It is now generally agreed that there 
is a deficit in insulin and IGF-1 signaling in AD brains, 
which leads to the question that has been hard to resolve: 
whether there is an insulin deficit or insulin resistance in the 
brain. Additionally, insulin and IGF-I have proved to have 
direct effects on AD pathogenic processes. They affect the 
metabolism and clearance of A, and reduce the formation 
of neurofibrillary tangles by regulating the levels of   
phosphorylated tau protein. This, in theory could give them 
potent neuroprotective characteristics [60, 61]. 
2.2. Insulin Production in the Central Nervous System 
  The majority of the body’s insulin is produced by the 
pancreas; however insulin can cross the BBB from the circu-
lation to the brain by a receptor-dependent mechanism [43, 
62, 63]. As levels of expression of insulin in brain are mod-
est compared to circulating levels, it is still believed that 
transport of peripheral insulin across the BBB and the conse-
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have significant roles in cerebral insulin signaling. Insulin 
binding activity has been identified in the brain in a number 
of species, including humans [64-66]. However, recent work 
by De La Monte and colleagues has supported that insulin 
produced in the brain plays a central role in insulin signaling 
in the central nervous system [23,67,68]. The two main insu-
lin actions in the brain are regulation of glucose intake and 
indirectly effects on cognitive functions. In an insulin resis-
tance condition, there is a reduced sensitivity to insulin, 
which leads to overproduction of insulin (hyperinsulinemia). 
Chronic peripheral hyperinsulinemia results in an increase of 
insulin in the cerebrospinal fluid (CSF) but reduced insulin 
signaling in brain [69]. 
2.3. Diabetes and AD – Pathology Studies 
  It is incontrovertible that diabetes, particularly T2D, and 
AD are coexistent diseases of the elderly. The association 
between diabetes mellitus, insulin resistance and the degree 
of hippocampal and amygdalar atrophy was investigated in 
Rotterdam study by volumetric magnetic resonance imaging 
[70]. In this population-based cohort study, subjects with 
diabetes mellitus showed more hippocampal and amygdalar 
atrophy compared to subjects without diabetes. Furthermore, 
increasing insulin resistance was associated with more 
amygdalar atrophy. T2D was associated with smaller hippo-
campal and amygdalar volume regardless of the degree of 
vascular pathology [70]. 
  In general, diabetes leads to its own type of neuropathol-
ogy, cerebral neuropathology of type-2 diabetes, which con-
sists of cerebrovascular and white matter pathology [71-73]. 
In this study, when postmortem pathological assessments 
were carried out, neuropathological analyses generally dem-
onstrated reduced levels of AD pathology (numbers of amy-
loid plaques and neurofibrillary tangles). This has now been 
reproduced in separate studies [8, 71, 74, 75]. Nelson and 
colleagues examined a large series of elderly diabetic and 
non-diabetic brains for the signature neuropathology of dia-
betes [71]. Diabetics had significantly more infarcts, indica-
tive of vascular damage, while these cases had significantly 
lower plaque scores, as measured by Consortium to Establish 
a Registry for Alzheimer Disease (CERAD) criteria, fewer 
tangles in the subiculum, and fewer neuritic plaques in the 
temporal lobe. Other brain regions had fewer tangles and 
plaques in diabetic cases, but these differences did not reach 
statistical significance [71]. A similar study examined for 
AD pathology (neuritic plaques and neurofibrillary tangles) 
in diabetics that were treated and untreated, and compared 
the results with non-diabetics [74]. Similar to the results of 
Nelson [71], less AD pathology was present in diabetics. The 
difference was most noticeable in diabetics that had received 
insulin and insulin combined with an oral anti-diabetic medi-
cation. A comparison of diabetic and non-diabetic subjects 
for the severity of neuritic plaques and neurofibrillary tan-
gles in the cerebral cortex and in the hippocampus found 
significantly fewer neuritic plaques and neurofibrillary tan-
gles in the cerebral cortex of those with T2D compared to 
non-diabetics. In the hippocampus, diabetics had signifi-
cantly lower plaque scores than non-diabetics, but the lower 
ratings of neurofibrillary tangles did not achieve statistical 
significance. This study did not show increased AD pathol-
ogy in subjects with an apolipoprotein E epsilon-4 allele 
(apoE4) genotype and diabetes compared to apoE4 without 
diabetes. 
  This raises the question whether diabetes can accelerate 
AD pathology, or there are common coexisting factors   
for both diseases. The reduced AD neuropathology in the 
brains of diabetics may indicate that treatments for diabetes 
are reversing the AD pathology. This is germane in deciding 
whether diabetic medications should be tested for treating 
non-diabetic AD patients. In a further neuropathology study, 
investigators examined relation of diabetes to the most 
common neuropathology causes of dementia, cerebral infarc-
tion and AD [75]. They found a relationship between diabe-
tes and cerebral infarction but not between diabetes and   
AD pathology in older persons. Their findings indicate   
that those with diabetes are more likely to acquire enhanced 
levels of cerebrovascular disease, but not differing amounts 
of AD pathology compared to those who do not have diabe-
tes [75]. At present, the data does not support the hypothesis 
that diabetes is a direct causal factor for AD. However, we 
will review the evidence that a defect in insulin and insulin 
signaling in the brain is a significant co-factor for AD. 
2.4. Interactions of Diabetes, Apolipoprotein E4 and AD 
  Vascular abnormalities including atherosclerosis are in-
creased in diabetics, and also are a feature of those possess-
ing the apoE4 allele. Possession of a single or two copies of 
the apoE4 allele is the most significant risk factor for devel-
oping sporadic AD [76, 77]. Subjects with at least one apoE4 
allele tend to have higher levels of atherosclerosis and vascu-
lar amyloid than apoE4 negative subjects [78, 79]. It has 
been suggested that there might be an interaction of diabetes 
and AD with apoE4, though studies have produced conflict-
ing data. In an AD population, diabetes had 13% incidence 
in a non-apoE4 population, and a 5% incidence in AD   
subjects with one apoE4 allele [80]. However, individuals 
with T2DM who possess an apoE4 allele have twice the risk 
of developing AD compared with non-diabetics subjects with 
an apoE4 allele [81]. 
  In a study of an Italian population aimed at the diagnosis 
and treatment of dementia, vascular factors such as hyperten-
sion and hypercholesterolemia were not found to be signifi-
cantly associated with disease progression, but, surprisingly, 
patients with diabetes had a 65% reduced risk of fast cogni-
tive decline compared to AD patients without diabetes. Their 
findings suggest a slower disease progression in AD patients 
with diabetes, when based on clinical progression of AD 
severity [82]. As most of the patients were being treated for 
diabetes, this again could suggest an effect of diabetic medi-
cation/treatment being beneficial for AD. 
2.5. Diabetes, AD and Vascular Dementia 
  We are still left with the conflicting situation that epide-
miological studies show increased frequency of dementia in 
diabetics, while the series of neuropathology studies did not 
show enhanced AD pathology in this same group [83-88]. 
The Rotterdam Study demonstrated a significantly higher 
incidence of dementia in patients with both insulin depend-
ent (T1D) diabetes and T2D compared to age-matched con-
trols [24, 89, 90]. These studies suggested diabetes doubled Consequences of Aberrant Insulin Regulation in the Brain  Current Neuropharmacology, 2011, Vol. 9, No. 4    697 
the risk of dementia. Interestingly, one of these studies dem-
onstrated a greater risk of dementia in subjects being treated 
with insulin [90]. The risk of both AD (with Relative Risk 
RR 1·5–27·0) and vascular dementia (RR 2·0–2·5) was found 
to be increased in subjects with T2D [91]. Some epidemiol-
ogical data suggest that enhanced incidence of AD in diabe-
tes may actually be due to vascular forms of dementia. Stud-
ies showed that there is a cluster of risk factors for T2D and 
vascular diseases, which include high blood glucose, obesity, 
hypertension, increased blood triglycerides and insulin resis-
tance. All of these factors, both individually and collectively, 
increase the risk not only of AD, but also vascular dementia 
[92, 93]. 
2.6. Hypertension is a Common Feature of T2D 
  The effect of antihypertensive drug use on dementia in a 
cohort of the population-based Rotterdam Study was investi-
gated [94]. They demonstrated that subjects taking anti-
hypertensive medication had a reduced incidence of demen-
tia. This reduction risk was most significant for vascular de-
mentia (VaD), not for AD. Both cerebrovascular disease and 
T2D decrease cognitive functioning in elderly people, but it 
is uncertain if T2D affects cognition independent of vascular 
disease. Patients with arterial disease and T2D performed 
worse on neuropsychological tests compared to similar pa-
tients without T2D [33]. Elevated systolic and diastolic 
blood pressures were significantly associated with decreased 
cognition in patients with T2D. Large infarcts and global   
and cortical atrophy on MRI were independently associated 
with cognition in patients with T2D. They concluded that   
the presence of T2D in patients with symptomatic arterial 
disease is associated with decreased cognitive functioning. 
Cerebrovascular disease and AD are common diseases of 
aging and frequently coexist in the same brain. 
3. BIOCHEMICAL MECHANISMS LINKING INSULIN 
AND AD 
3.1. RAGE, Diabetes and AD 
  A common pathological feature between diabetes and 
AD has been the presence of advanced glycation endproduct 
(AGE)-modified proteins in both diseases [47, 95]. These 
modified proteins are ligands for the receptor for advanced 
glycation endproducts (RAGE), as is A peptide [96]. 
RAGE, was first recognized as a cell surface receptor for the 
products of non-enzymatic glycation and oxidation of pro-
teins, being involved in many inflammatory process, and is a 
component of major histocompatibility complex (MHC) 
gene cluster [97]. RAGE expression is influenced by patho-
logical conditions such as diabetic vascular disease, chronic 
inflammation and AD [98, 99], as its interaction with AGE-
modified proteins in either diabetes or AD, or A in AD, has 
the potential to produce damaging inflammatory responses 
[100, 101]. In multiple studies of diabetes or AD models, it 
has been shown that increased presence of RAGE ligands 
leads to pro-inflammatory activation by RAGE-expressing 
cells; also with the consequence of increasing amounts of 
RAGE being expressed. Furthermore, this interaction be-
tween RAGE and its ligands triggers the activation of a key 
cell signaling pathway, such as p21
ras and transcription factor 
nuclear factor-kappa B (NF-B).  
  The activation of NF-B is considered to be the most 
common feature in RAGE signaling, as it up regulates cellu-
lar expression of RAGE [100, 101]. The extent that this hap-
pens in vivo is still unclear, but increased RAGE expression 
along with increased amounts of AGE-modified proteins is 
believed to be a major cause of the vascular complications 
that are a common feature of diabetes and AD [102-107]. In 
diabetes, the elevated blood glucose level promotes forma-
tion of advanced glycation end products (AGEs). Continuous 
hyperglycemia is a causative factor for diabetic vascular 
complications primarily due to the enhanced generation of 
advanced glycation end-products (AGEs). Different types of 
AGE-modifications can occur; recent evidence suggests that 
glyceraldehyde-derived AGEs (glycer-AGE) are the pre-
dominant modification of the most toxic forms of AGEs 
(TAGE). Glycer-AGE-modified proteins are directly toxic to 
cultured neurons; diabetic serum enriched in glycer-AGE 
modified proteins was also toxic to neurons, an effect that 
could be neutralized with antibody to glycer-AGE. Moreo-
ver, increased amounts of these modified proteins were de-
tectable by immunocytochemistry in AD hippocampus tissue 
sections [95, 108-110]. On the other hand, immunohisto-
chemistry for RAGE in AD brains has been demonstrated 
with increased expression in neurons, microglia, astrocytes 
and vascular endothelial cells [96, 111-114]. It has been 
shown that RAGE is a receptor for A [96], and it mediates 
the transport of plasma A across the BBB [115], supported 
by the evidence that the blockade of RAGE on brain vascular 
endothelial cells reduce transport of peripheral circulating 
A into the brain [92]. In addition, the migration of mono-
cytes across the human brain endothelial cells in response to 
A was mediated by RAGE [116]. 
3.2. Insulin Signaling and A 
  As studies have concluded that diabetic neuropathology 
and AD are separate entities, the mechanism of insulin’s 
involvement in AD needs to be resolved. As mentioned, up 
to 80% of AD patients have type II insulin resistance diabe-
tes (T2D). In T2D, there is an excess production of insulin 
due to the insulin receptors becoming unresponsive to insulin 
binding. The increased production of insulin can compensate 
for the lack of signaling to some extent, but this excess insu-
lin is degraded by the pool of IDE, which also functions to 
degrade monomeric A. This results in increased levels of 
both, and the resulting lack of insulin signaling. Blocking 
insulin signaling results in reduced glucose metabolism, in-
creased glycogen synthase kinase-3 (GSK-3) activation 
which can promote hypophosphorylation of tau and in-
creased A production. It has even been suggested that insu-
lin can promote A aggregation. The possible interactions of 
insulin and A on insulin signaling are shown in Fig. (2). 
The effects of excess type A is generated as a result of pro-
teolytic cleavage of amyloid precursor protein (APP) and has 
been considered the main toxic mediating factor in AD. It 
has been shown that A binds to a number of neuronal or 
glial receptors (reviewed [117, 118]), including the insulin 
receptor. It appears that monomeric A can compete with 
insulin for the neuronal insulin receptor [119], with the con-
sequence of reduced insulin receptor signaling. Recent stud-
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forms of A known as Abeta derived diffusible ligands 
(ADDL), with neuronal insulin receptors have suggested as a 
neurotoxic mechanism in AD. Extracellular ADDLs have 
been shown to bind to and inhibit insulin receptor signaling. 
Binding of ADDLs to synaptic insulin receptors on cultured 
neurons resulted in their rapid loss from the plasma mem-
brane and their internalization. Intracellular ADDLs can in-
hibit phosphoinositide-dependent kinase 1 and Akt1, pre-
venting Akt1-mediated cellular signaling, a pathway central 
for insulin signaling [120,121]. Moreover, it activates 
GSK3, which has many substrates including IRS-1, result-
ing in impaired insulin signaling. In a study to test the hy-
pothesis that insulin signaling provides a protective mecha-
nism against ADDLs toxicity, it was shown that the neuro-
toxic effects of ADDLs could be competitively inhibited 
with insulin, or with suboptimal doses of insulin combined 
with the insulin receptor sensitizing drug rosiglitozone, by 
blocking ADDLs binding to synapses [122]. As it is hard to 
maintain the insulin balance in the brain with aging, since 
insulin signaling tends to decline, this might be the main risk 
factor for developing AD. Therefore, new insulin focused 
therapeutic interventions need to be explored to determine if 
they can preserve brain function [99]. Features of failed insu-
lin signaling in the brain and the potential AD-related conse-
quences are illustrated in Fig. (2).  
3.3. Insulin Degrading Enzyme in Diabetes and AD 
  When considering the potential interactions between dia-
betes, particularly hyperinsulinemia, and AD, the most con-
vincing evidence has come from a range of studies on insulin 
degrading enzyme (IDE). IDE also referred to as insulysin or 
insulin protease, is a zinc binding metalloprotease involved 
in regulating insulin levels and is one of the proteases in-
volved in A degradation (primarily the monomeric and 
soluble forms of A) [123-127]. Mutations in the IDE gene 
that result in reduced activity of the enzyme and lead to dia-
betes in a rat model of T2DM also result in enhanced cere-
bral deposition of A [128]. IDE has additional substrates 
including insulin-like growth factor (IGF-II), amylin, gluca-
gon, transforming growth factor alpha and beta endorphin, 
which will affect its affinity for insulin or A [129]. The 
hypothesis of the interactions of IDE, insulin and A/AD has 
come from studies on T2D. In such a condition with hyperin-
sulinemia, where cells are not sensitive to insulin regulation, 
the extra insulin produced competes for the IDE and lowers 
the amount available for A degradation [130]. This mecha-
nism has been demonstrated in a transgenic model of insulin 
resistant diabetes [131]. Hence, this could be a mechanism 
for increased build up of A, the most established pathologi-
cal feature of AD. There is an interesting interaction between 
insulin, IDE and cholesterol metabolism. Mice fed a high fat 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Consequences of insulin and A interactions on reduced neuronal insulin receptor signaling and promoting Alzheimer’s 
disease pathology. In type 2 diabetes, there can be decreased or increased levels of insulin in brain (depending on disease state), along with 
insulin receptor desensitization. A peptide levels can be enhanced by reduced insulin receptor signaling, and soluble A oligomers can also 
block these receptors. Increased A levels will compete for insulin degrading enzyme with cerebral insulin. A aggregates can also have 
direct membrane toxic effect on neuronal cells. Reduced insulin receptor signaling results in reduced PI-3K activity that leads to reduced 
PKB/AKT activity. The consequences of this include reduced glucose metabolism and increased oxidative stress. Specifically reduced GSK3 
phosphorylation leads to increased tau phosphorylation and A formation. 
Abbreviations: PI- 3K- phosphoinositide-3 kinase: PKB/AKT – protein kinase B; GSK3 – glycogen synthase kinase 3:  A  amyloid beta 
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diet had reduced IDE mRNA and protein expression and 
elevated A levels, while in humans, lowest levels of IDE 
(and neprilysin, the other major A degrading enzyme) were 
in AD cases that were homozygous for Apo 4 allele 
[132,133]. 
3.4. Insulin Resistance Syndrome, Memory and Inflam-
mation 
  Insulin resistance syndrome is a condition in which there 
is an impaired response of body cells (muscle, fat, and he-
patic) to insulin resulting in impaired endothelial function 
and enhanced atherosclerosis [134-138]; which requires 
higher doses of insulin for normal function. Insulin is known 
for its significant role in establishing and preserving brain 
memory [139]. With aging and other memory impairment 
diseases (as in AD), insulin levels increase in the plasma, 
while it tends to decrease in the CSF and has reduced activity 
in the brain [140] . Insulin resistance and hyperinsulinemia 
have proved to be risk factors for both general memory de-
cline and AD [87,141]. Furthermore, studies have revealed 
that during a chronic insulin resistance state or chronic in-
flammation, insulin may aggravate inflammatory responses, 
increase markers of oxidative stress and lead to the formation 
of superoxide anions [141-143]. The administration of insu-
lin has resulted in increased plasma concentrations of C-
reactive protein and pro-inflammatory cytokines (IL-1, IL-
6, and tumor necrosis factor  [TNF] [144]. 
3.5. Glucose, Insulin and Memory 
  The human brain uses up to 25% of total body glucose, 
as it is the main nutrient for maintaining brain function 
[145]. However, hyperglycemia leads to many pathological 
changes. One biomarker for studying hyperglycemia in liv-
ing patients is serum glycohemoglobin (HbA1C) [146-148]. 
These studies were carried out in different populations, but 
showed that uncontrolled diabetes/hyperglycemia as shown 
by elevated HbA1C correlated significantly with declines in 
cognitive function. As reviewed, the mechanisms that medi-
ate the toxic effects of hyperglycemia are varied, but include 
the accumulation of AGEs; increases in reactive oxygen spe-
cies (ROS) production; enhanced vascular inflammation 
leading to microvascular changes that can result in microin-
farcts and generalized brain atrophy. This supports the hy-
pothesis that glycemic control is the cornerstone in maintain-
ing functional memory in patients with T2D [149]. 
3.6. Animal Models for CNS Insulin Signaling Deficits   
in AD 
  One of the problems of human clinical studies of diabetes 
and AD has been the fact that measurements of glucose   
metabolism and insulin levels at the time of death in an   
AD patient are not reflective of the pathological mechanisms 
that lead to this stage. Most of the metabolic processes will 
have been altered prior to death. For this reason, relevant 
animal models have been invaluable for dissecting insulin 
related mechanisms in the CNS and whether they predispose 
to AD. 
  A widely used reagent for inducing experimental diabetes 
is streptozotocin, broad spectrum antibiotics with a nitrosa-
mine-related compound that destroys beta cells in the pan-
creatic islets. Injection of streptozotocin into the ventricles of 
the brains of rats resulted in 10-30% reduction in glucose 
metabolism. The mechanism of this cytotoxic diabetogenic 
drug is mainly mediated by the development of ROS, in ad-
dition to the formation of nitric oxide (NO), which induces 
destruction by necrosis [150]. It is presumed that the same 
mechanism occuring in the pancreas occurs in the brain. The 
widely used transgenic A plaque-developing mouse models 
of AD have been used in a number of studies to demonstrate 
how insulin resistance or deficiency can accelerate plaque 
deposition and memory impairment. The key studies are 
reviewed below while considering different insulin related 
mechanisms. However, the interpretation of these findings as 
they relate to the human diabetic needs to be interpreted 
carefully before considering the indicated therapeutic   
approaches. Although widely used, there are limitations   
to these mouse models of AD as they relate to the human 
disease. 
3.6.1. Transgenic Mice and Insulin Degrading Enzyme 
  Increased generation of A appears to stimulate expres-
sion of IDE in AD transgenic mice model. As plaque forma-
tion progresses, IDE levels increase. This was particularly 
noticeable with the increased numbers of IDE-immuno- 
reactive astrocytes surrounding plaques [151]. These investi-
gators showed that A could directly stimulate IDE expres-
sion by astrocytes in vitro. This finding contrasts with the 
decrease in IDE shown in human AD brains [132]. This find-
ing was replicated in another study where increased expres-
sion of IDE occurred with the progressive increased accumu-
lation of A levels in a transgenic mouse model [152]. Of 
more relevance, using Tg2576 mice that had been fed a diet 
that induces type-2 like insulin resistance, these animals had 
enhanced levels of A compared to control animals, and this 
treatment also resulted in lower levels of IDE [131]. 
3.6.2. Transgenic Mice and Insulin Signaling 
  Studies of insulin deficiency, as a model of type 1 diabe-
tes, in transgenic mice provided some parallel features with 
AD. Nine weeks of insulin deficiency resulted in reduced 
IDE, reduced learning capacity, and reduced insulin receptor 
signaling. Reduced insulin signaling resulted in increased tau 
phosphorylation and A levels. These effects were partially 
reversed with insulin treatment. These pathological features 
were not observed in a parallel T2D model [153]. Two new 
transgenic mouse models have been produced that demon-
strate how AD pathology can exacerbate insulin signaling 
deficiencies and glucose tolerance and how diabetes can en-
hance cerebrovascular A deposition and amyloid mediated 
vascular inflammation. Crossing APP23 transgenic mice 
with ob/ob (leptin deficient) mice resulted in enhanced dia-
betes symptoms (blood glucose levels and plasma insulin) 
compared to ob/ob mice alone, but with reduced insulin lev-
els in the brain. These mice also had significantly reduced 
cognitive function and insulin signaling, even though there 
was no increased A compared to APP non-diabetic mice. 
Similarly, crossing APP23 with the mouse model of T2D 
(Nagoya-Shibata-Yasuda (NSY)) resulted in more severe 
memory deficits and insulin resistance compared to NSY 
mice. In this model, brain A levels correlated positively 
with circulating glucose levels. This study concluded that the 
enhancement of A-associated memory impairment and pa-700    Current Neuropharmacology, 2011, Vol. 9, No. 4  Arab et al. 
thology in these mouse models was due to increased cere-
brovascular inflammation mediated by increased RAGE ex-
pression on endothelial cells. It still remains to be deter-
mined how vascular inflammation can affect insulin signal-
ing, but this and other studies suggest that it can reduce BBB 
transport of insulin into brain [154]. Two recent studies in-
vestigating the effect of T1D on amyloid plaque developing 
transgenic mice came to similar conclusions that diabetes/ 
insulin deficiency was exacerbating the AD-like pathology 
[155, 156]. Both induced T1D by injections of streptozooto-
cin, one by intraperitoneal injection [156], and the other by 
intracerebral injection [155]. Both studies showed reduction 
of cognitive measures and enhanced levels of phosphorylated 
tau and A plaques. Similarly, using a different genetic 
mouse model that develops tangles, not plaques, due the 
presence of the P301L tau mutation, streptozootocin-induced 
T1D accelerated the formation of phosphorylated tau and 
tangle formation [157]. At present, it is hard to determine 
which mouse model of the interaction of insulin signaling 
defects and AD best reflects the human condition. As dis-
cussed, diabetes in humans does not appear to enhance AD 
neuropathology. In this final section, we will discuss how 
insulin focused therapy might be effective in treating some 
of the clinical manifestations of AD.  
4. NEUROPHARMACOLOGY OF INSULIN THERAPY 
  The literature on diabetes, dementia and therapy has 
drawn many divergent conclusions possibly due to the differ-
ing designs of the clinical studies. To address the issue 
whether insulin therapy or anti-diabetic medication could 
affect cognitive function, a group of AD patients with T2D 
were either treated with anti-diabetic medication, or with 
insulin and anti-diabetic medication. After 12 months, the 
group receiving insulin and anti-diabetic medication had 
deteriorated at half the rate of those receiving the non-insulin 
therapy [158]. Another recent study that showed that the rate 
of cognitive decline in AD patients with diabetes was sig-
nificantly less than those without appeared to conflict with 
the previous study, however the patients with diabetes were 
being treated with insulin and/or anti-diabetic medication 
(though the percentages were not reported) [159], so the 
findings of both papers that diabetic/insulin medication is 
useful for treating AD cognitive decline may be similar. 
4.1. Current Treatment Plans for DM and AD 
  The treatment strategies that are now used in AD are 
mainly targeting symptom improvement. AD has a major 
inflammatory component due to the neurodegeneration and 
A peptide deposition. As a result, many studies have shown 
that non-steroidal anti inflammatory drugs (NSAIDs) may 
affect AD process, and may reduce the risk and delay the 
onset of AD. Some NSAIDs are also ligands for peroxisome 
proliferator activated receptors (especially the PPAR) [54, 
132, 160, 161]. 
  PPARs are ligand-inducible transcription factors that 
regulate the expression of a number of inflammatory and 
insulin-regulated genes [160]. The best-known PPAR ligands 
are the thiazolidinediones such as rosiglitazone and pioglita-
zone, which are insulin sensitizers and are used in the treat-
ment of T2D. Recent studies have shown that pharmacologi-
cal treatment with thiazolidinediones may offer some thera-
peutic answers for AD by lowering peripheral insulin and 
improving insulin sensitivity [162-165]. Furthermore, these 
agonists of the nuclear receptor have also been shown to 
reduce A accumulation, inflammatory reactants and exhibit 
neuroprotective effects in animal models [163, 164, 166]. In 
a prospective randomized, open-controlled study, 32 diabetic 
patients with mild to moderate AD were enrolled. Subjects 
treated with insulin were excluded. Patients were randomly 
assigned to the treatment with pioglitazone, as they were not 
taking any medication known to affect cognition or behavior 
during the study. Results showed significant cognitive and 
metabolic improvements in diabetic patients with AD after 6 
months of taking pioglitazone compared with a control group 
[162]. Another randomized study in mild to moderate AD 
patients was conducted using rosiglitazone [167]. Results 
were stratified by apoE genotype. This study detected no 
significant statistical differences between placebo and any 
rosiglitazone (RSG) dose at baseline. However, there was a 
significant interaction between apoE4 allele status and As-
sessment Scale-Cognitive (ADAS-Cog). It showed a signifi-
cant improvement in ADAS-Cog in apoE4-negative patients 
on a high dose of RSG (P=0.024) while apoE4-positive   
patients showed a decline at the lowest RSG dose (P=0.012). 
These results showed that apoE4 non-carriers might be   
the only subjects that would have cognitive and functional 
improvement in response to RSG [167]. 
  Recent findings on the safety of rosiglitazone might   
preclude this drug for further testing in AD, but alternative 
drugs of this family with similar modes of action are   
available. 
4.2. Effects of Intranasal Administration of Insulin   
on Cognition and AD  
  Another new approach in treating AD is in the admini-
stration of intranasal insulin. The fact that there are direct 
pathways between the nasal cavity and the central nervous 
system has guaranteed an easy access for insulin through the 
BBB, without the risk of systemic hypoglycemia that results 
from the peripheral administration of insulin [7]. In this 
study, insulin levels increased in the CSF 10 minutes after 
the intranasal administration with peak levels in 30 minutes 
[7]. Recent studies were conducted on patients with mild 
cognitive impairment and AD using intranasal insulin. Find-
ings have shown that the administration of intranasal insulin 
in average dose of 20 IU acutely benefits the verbal memory 
in non apoE4 carriers. On the contrary, to relative decline or 
no benefit in apoE4 carriers. These findings suggest that 
dose-response is different by apoE4 genotypes, which could 
be due to insulin sensitivity differences that are common in 
non apoE4 AD patients [7].  
CONCLUSION 
  Initially, insulin was thought to not cross the BBB as the 
brain was perceived to be an insulin–insensitive organ, how-
ever this was shown not to be true. It is still probable that 
most insulin in the brain is transported from the periphery 
but further studies on CNS synthesized insulin are needed 
[168]. Insulin has proved to be a crucial element for neuro-
logical functions. T2D and chronic peripheral hyperinsu-
linemia are associated with impairment in memory and cog-
nitive functions. The exact pathophysiology of cognitive Consequences of Aberrant Insulin Regulation in the Brain  Current Neuropharmacology, 2011, Vol. 9, No. 4    701 
dysfunction and cerebral lesions in diabetes mellitus is not 
completely understood. However, hyperglycemia, vascular 
disease, and insulin resistance are considered to be the main 
factors [169]. Diabetes and AD appear to have common fea-
tures, and some authors refer to AD as type 3 diabetes. The 
factors that support the relationship between T2D and AD 
are insulin resistance, altered brain IDE levels, A clearance 
and AGEs formation. Treatment strategies for both diseases 
have been considered, because of the shared features. Dia-
betic medications have been explored as treatment candi-
dates for AD. Insulin-sensitizing agents (ligands for PPAR) 
and intranasal insulin have been the most recent candidates, 
though insulin-sensitizing agents now appear to have limited 
effects and significant side effects. However, they have of-
fered a potential but limited therapeutic solution, and more 
research on patients with both diseases is needed to answer 
the questions being proposed on insulin and AD. 
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A  =  Amyloid beta peptide 
AChE = Acetylcholinesterase 
AD =  Alzheimer’s  Disease 
ADDL  =  Abeta Derived Diffusible Ligands 
BBB  =  Blood Brain Barrier 
CSF =  Cerebrospinal  Fluid 
FDG =  Fluorodeoxyglucose 
HbAIC =  Glycohemoglobin 
IGF  =  Insulin-Like Growth Factor 
IDE =  Insulin  Degrading  Enzyme 
NO =  Nitric  Oxide 
PD =  Parkinson  Disease 
PET =  Positron  Emission  Tomography 
PPAR = Peroxisome  Proliferator-Actived  Receptor 
RAGE  =  Receptor for advanced glycation endproducts 
ROS =  Reactive  Oxygen  Species 
T1D  =  Type 1 Diabetes  
T2D  =  Type 2 Diabetes  
REFERENCES 
[1]  Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.;   
Evans, D. A. Alzheimer disease in the US population: prevalence  
estimates using the 2000 census. Arch. Neurol., 2003, 60, 1119-
1122. 
[2]  Hebert, L. E.; Beckett, L. A.; Scherr, P. A.; Evans, D. A. Annual 
incidence of Alzheimer disease in the United States projected to the 
years 2000 through 2050. Alzheimer Dis. Assoc. Disord., 2001, 15, 
169-173. 
[3]  Bianchetti, A.; Ranieri, P.; Margiotta, A.; Trabucchi, M. Pharma-
cological treatment of Alzheimer's Disease. Aging Clin. Exp. Res., 
2006, 18, 158-162. 
[4]  Karow, D. S.; McEvoy, L. K.; Fennema-Notestine, C.; Hagler,   
D. J., Jr.; Jennings, R. G.; Brewer, J. B.; Hoh, C. K.; Dale, A. M. 
Relative Capability of MR Imaging and FDG PET to Depict 
Changes Associated with Prodromal and Early Alzheimer Disease. 
Radiology, 2010, 256, 932-942. 
[5]  Mosconi, L.; Berti, V.; Glodzik, L.; Pupi, A.; De, S. S.; de Leon, 
M. J. Pre-clinical detection of Alzheimer's disease using FDG-PET, 
with or without amyloid imaging. J. Alzheimers Dis., 2010, 20, 
843-854. 
[6]  Hoffman, J. M.; Guze, B. H.; Baxter, L. R.; Mazziotta, J. C.; 
Phelps, M. E. [18F]-fluorodeoxyglucose (FDG) and positron emis-
sion tomography (PET) in aging and dementia. A decade of studies. 
Eur. Neurol., 1989, 29(Suppl 3), 16-24. 
[7]  Reger, M. A.; Watson, G. S.; Green, P. S.; Wilkinson, C. W.; 
Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Breitner, 
J. C.; DeGroodt, W.; Mehta, P.; Craft, S. Intranasal insulin   
improves cognition and modulates beta-amyloid in early AD.   
Neurology, 2008, 70, 440-448. 
[8]  Beeri, M. S.; Silverman, J. M.; Davis, K. L.; Marin, D.; Grossman, 
H. Z.; Schmeidler, J.; Purohit, D. P.; Perl, D. P.; Davidson, M.; 
Mohs, R. C.; Haroutunian, V. Type 2 diabetes is negatively associ-
ated with Alzheimer's disease neuropathology. J. Gerontol. A Biol. 
Sci. Med. Sci., 2005, 60, 471-475. 
[9]  Jagust, W. J.; Landau, S. M.; Shaw, L. M.; Trojanowski, J. Q.; 
Koeppe, R. A.; Reiman, E. M.; Foster, N. L.; Petersen, R. C.; 
Weiner, M. W.; Price, J. C.; Mathis, C. A. Relationships between 
biomarkers in aging and dementia. Neurology,  2009,  73,  1193-
1199. 
[10]  Langbaum, J. B.; Chen, K.; Lee, W.; Reschke, C.; Bandy, D.; Flei-
sher, A. S.; Alexander, G. E.; Foster, N. L.; Weiner, M. W.; 
Koeppe, R. A.; Jagust, W. J.; Reiman, E. M. Categorical and corre-
lational analyses of baseline fluorodeoxyglucose positron emission 
tomography images from the Alzheimer's Disease Neuroimaging 
Initiative (ADNI). Neuroimage., 2009, 45, 1107-1116. 
[11]  Haense, C.; Buerger, K.; Kalbe, E.; Drzezga, A.; Teipel, S. J.; 
Markiewicz, P.; Herholz, K.; Heiss, W. D.; Hampel, H. CSF total 
and phosphorylated tau protein, regional glucose metabolism and 
dementia severity in Alzheimer's disease. Eur. J. Neurol., 2008, 15, 
1155-1162. 
[12]  Chertkow, H.; Black, S. Imaging biomarkers and their role in   
dementia clinical trials. Can. J. Neurol. Sci.,  2007,  34(Suppl 1), 
S77-S83. 
[13]  Rabinovici, G. D.; Jagust, W. J. Amyloid imaging in aging and 
dementia: testing the amyloid hypothesis in vivo. Behav. Neurol., 
2009, 21, 117-128. 
[14]  Petrie, E. C.; Cross, D. J.; Galasko, D.; Schellenberg, G. D.; 
Raskind, M. A.; Peskind, E. R.; Minoshima, S. Preclinical evidence 
of Alzheimer changes: convergent cerebrospinal fluid biomarker 
and fluorodeoxyglucose positron emission tomography findings. 
Arch. Neurol., 2009, 66, 632-637. 
[15]  Mosconi, L.; Mistur, R.; Switalski, R.; Brys, M.; Glodzik, L.; Rich, 
K.; Pirraglia, E.; Tsui, W.; De, S. S.; de Leon, M. J. Declining brain 
glucose metabolism in normal individuals with a maternal history 
of Alzheimer disease. Neurology, 2009, 72, 513-520. 
[16]  Caselli, R. J.; Chen, K.; Lee, W.; Alexander, G. E.; Reiman, E. M. 
Correlating cerebral hypometabolism with future memory decline 
in subsequent converters to amnestic pre-mild cognitive impair-
ment. Arch. Neurol., 2008, 65, 1231-1236. 
[17]  Mosconi, L.; Perani, D.; Sorbi, S.; Herholz, K.; Nacmias, B.; Holt-
hoff, V.; Salmon, E.; Baron, J. C.; De Cristofaro, M. T.; Padovani, 
A.; Borroni, B.; Franceschi, M.; Bracco, L.; Pupi, A. MCI conver-
sion to dementia and the APOE genotype: a prediction study with 
FDG-PET. Neurology, 2004, 63, 2332-2340. 
[18]  Ishii, K.; Sasaki, H.; Kono, A. K.; Miyamoto, N.; Fukuda, T.; Mori, 
E. Comparison of gray matter and metabolic reduction in mild Alz-
heimer's disease using FDG-PET and voxel-based morphometric 
MR studies. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 959-963. 
[19]  Bingham, E. M.; Hopkins, D.; Smith, D.; Pernet, A.; Hallett, W.; 
Reed, L.; Marsden, P. K.; Amiel, S. A. The role of insulin in hu-
man brain glucose metabolism: an 18fluoro-deoxyglucose positron 
emission tomography study. Diabetes, 2002, 51, 3384-3390. 
[20]  Kawasaki, K.; Ishii, K.; Saito, Y.; Oda, K.; Kimura, Y.; Ishiwata, 
K. Influence of mild hyperglycemia on cerebral FDG distribution 
patterns calculated by statistical parametric mapping. Ann. Nucl. 
Med., 2008, 22, 191-200. 702    Current Neuropharmacology, 2011, Vol. 9, No. 4  Arab et al. 
[21]  Cardoso, S.; Correia, S.; Santos, R. X.; Carvalho, C.; Santos, M. S.; 
Oliveira, C. R.; Perry, G.; Smith, M. A.; Zhu, X.; Moreira, P. I. In-
sulin is a Two-Edged Knife on the Brain. J. Alzheimers Dis., 2009, 
18, 483-507. 
[22]  Gerozissis, K. Brain insulin, energy and glucose homeostasis; 
genes, environment and metabolic pathologies. Eur. J. Pharmacol., 
2008, 585, 38-49. 
[23]  Steen, E.; Terry, B. M.; Rivera, E. J.; Cannon, J. L.; Neely, T. R.; 
Tavares, R.; Xu, X. J.; Wands, J. R.; de la Monte, S. M. Impaired 
insulin and insulin-like growth factor expression and signaling 
mechanisms in Alzheimer's disease--is this type 3 diabetes? J. Alz-
heimers Dis., 2005, 7, 63-80. 
[24]  Ott, A.; Stolk, R. P.; Hofman, A.; van, H. F.; Grobbee, D. E.; Bre-
teler, M. M. Association of diabetes mellitus and dementia: the 
Rotterdam Study. Diabetologia, 1996, 39, 1392-1397. 
[25]  Tanti, J. F.; Jager, J. Cellular mechanisms of insulin resistance: role 
of stress-regulated serine kinases and insulin receptor substrates 
(IRS) serine phosphorylation.  Curr. Opin. Pharmacol., 2009,  9, 
753-762. 
[26]  Gogg, S.; Smith, U.; Jansson, P. A. Increased MAPK activation 
and impaired insulin signaling in subcutaneous microvascular en-
dothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes, 
2009, 58, 2238-2245. 
[27]  Boura-Halfon, S.; Zick, Y. Phosphorylation of IRS proteins, insulin 
action, and insulin resistance. Am. J. Physiol Endocrinol. Metab, 
2009, 296, E581-E591. 
[28]  Lebrun, P.; Van, O. E. SOCS proteins causing trouble in insulin 
action. Acta Physiol (Oxf), 2008, 192, 29-36. 
[29]  Janson, J.; Laedtke, T.; Parisi, J. E.; O'Brien, P.; Petersen, R. C.; 
Butler, P. C. Increased risk of type 2 diabetes in Alzheimer disease. 
Diabetes, 2004, 53, 474-481. 
[30]  de la Monte, S. M.; Wands, J. R. Alzheimer's disease is type 3 
diabetes-evidence reviewed. J.  Diabetes Sci. Technol.,  2008, 2 , 
1101-1113. 
[31]  Bruehl, H.; Wolf, O. T.; Sweat, V.; Tirsi, A.; Richardson, S.; Con-
vit, A. Modifiers of cognitive function and brain structure in mid-
dle-aged and elderly individuals with type 2 diabetes mellitus. 
Brain Res., 2009, 1280, 186-194. 
[32]  Pasquier, F.; Boulogne, A.; Leys, D.; Fontaine, P. Diabetes mellitus 
and dementia. Diabetes Metab., 2006, 32, 403-414. 
[33]  Tiehuis, A. M.; Mali, W. P.; van Raamt, A. F.; Visseren, F. L.; 
Biessels, G. J.; van Zandvoort, M. J.; Kappelle, L. J.; van der, G. Y. 
Cognitive dysfunction and its clinical and radiological determinants 
in patients with symptomatic arterial disease and diabetes. J.  
Neurol. Sci., 2009, 283, 170-174. 
[34]  de la Monte, S. M. Insulin resistance and Alzheimer's disease.   
BMB Rep., 2009, 42, 475-481. 
[35]  Hallschmid, M.; Schultes, B. Central nervous insulin resistance: a 
promising target in the treatment of metabolic and cognitive disor-
ders? Diabetologia, 2009, 52, 2264-2269. 
[36]  Liao, F. F.; Xu, H. Insulin signaling in sporadic Alzheimer's   
disease. Sci. Signal., 2009, 2, e36. 
[37]  Naderali, E. K.; Ratcliffe, S. H.; Dale, M. C. Obesity and Alzheimer's 
disease: a link between body weight and cognitive function in old 
age. Am. J. Alzheimers. Dis. Other Demen., 2009, 24, 445-449. 
[38]  Salkovic-Petrisic, M.; Osmanovic, J.; Grunblatt, E.; Riederer, P.; 
Hoyer, S. Modeling Sporadic Alzheimer's Disease: The Insulin   
Resistant Brain State Generates Multiple Long-Term Morphobi-
ological Abnormalities Inclusive Hyperphosphorylated Tau Protein 
and Amyloid-beta. A Synthesis. J. Alzheimers. Dis., 2009, 18(4): 
729-750. 
[39]  Zhao, W. Q.; Townsend, M. Insulin resistance and amyloido- 
genesis as common molecular foundation for type 2 diabetes   
and Alzheimer's disease. Biochim. Biophys. Acta, 2009, 1792, 482-
496. 
[40]  Starr, V. L.; Convit, A. Diabetes, sugar-coated but harmful to the 
brain. Curr. Opin. Pharmacol., 2007, 7, 638-642. 
[41]  Grossman, H. Does diabetes protect or provoke Alzheimer's dis-
ease? Insights into the pathobiology and future treatment of Alz-
heimer's disease. CNS. Spectr., 2003, 8, 815-823. 
[42]  Zhao, L.; Teter, B.; Morihara, T.; Lim, G. P.; Ambegaokar, S. S.; 
Ubeda, O. J.; Frautschy, S. A.; Cole, G. M. Insulin-degrading en-
zyme as a downstream target of insulin receptor signaling cascade: 
implications for Alzheimer's disease intervention. J. Neurosci., 
2004, 24, 11120-11126. 
[43]  Yu, Y.; Kastin, A. J.; Pan, W. Reciprocal interactions of insulin  
and insulin-like growth factor I in receptor-mediated transport 
across the blood-brain barrier. Endocrinology,  2006,  147, 2611-
2615. 
[44]  Fernandez-Gamba, A.; Leal, M. C.; Morelli, L.; Castano, E. M. 
Insulin-degrading enzyme: structure-function relationship and its 
possible roles in health and disease. Curr. Pharm. Des., 2009, 15, 
3644-3655. 
[45]  Kojro, E.; Postina, R. Regulated proteolysis of RAGE and AbetaPP 
as possible link between type 2 diabetes mellitus and Alzheimer's 
disease. J. Alzheimers Dis., 2009, 16, 865-878. 
[46]  Yamagishi, S.; Nakamura, K.; Matsui, T.; Noda, Y.; Imaizumi, T. 
Receptor for advanced glycation end products (RAGE): a novel 
therapeutic target for diabetic vascular complication. Curr. Pharm. 
Des., 2008, 14, 487-495. 
[47]  Taguchi, A. Vascular factors in diabetes and Alzheimer's disease. J. 
Alzheimers. Dis., 2009, 16, 859-864. 
[48]  Ma, Q. L.; Yang, F.; Rosario, E. R.; Ubeda, O. J.; Beech, W.; Gant, 
D. J.; Chen, P. P.; Hudspeth, B.; Chen, C.; Zhao, Y.; Vinters, H. 
V.; Frautschy, S. A.; Cole, G. M. Beta-amyloid oligomers induce 
phosphorylation of tau and inactivation of insulin receptor substrate 
via c-Jun N-terminal kinase signaling: suppression by omega-3 
fatty acids and curcumin. J. Neurosci., 2009, 29, 9078-9089. 
[49]  Zhao, W. Q.; Lacor, P. N.; Chen, H.; Lambert, M. P.; Quon, M. J.; 
Krafft, G. A.; Klein, W. L. Insulin receptor dysfunction impairs 
cellular clearance of neurotoxic oligomeric a{beta}. J. Biol. Chem., 
2009, 284, 18742-18753. 
[50]  Jolivalt, C. G.; Lee, C. A.; Beiswenger, K. K.; Smith, J. L.; Orlov, 
M.; Torrance, M. A.; Masliah, E. Defective insulin signaling path-
way and increased glycogen synthase kinase-3 activity in the brain 
of diabetic mice: parallels with Alzheimer's disease and correction 
by insulin. J. Neurosci. Res., 2008, 86, 3265-3274. 
[51]  Townsend, M.; Mehta, T.; Selkoe, D. J. Soluble Abeta inhibits 
specific signal transduction cascades common to the insulin recep-
tor pathway. J. Biol. Chem., 2007, 282, 33305-33312. 
[52]  Liao, F. F.; Xu, H. Insulin signaling in sporadic Alzheimer's   
disease. Sci. Signal., 2009, 2, e36. 
[53]  Cardoso, S.; Correia, S.; Santos, R. X.; Carvalho, C.; Santos, M. S.; 
Oliveira, C. R.; Perry, G.; Smith, M. A.; Zhu, X.; Moreira, P. I. In-
sulin is a Two-Edged Knife on the Brain. J. Alzheimers. Dis., 2009, 
18, 483-507. 
[54]  Landreth, G. Therapeutic use of agonists of the nuclear receptor 
PPARgamma in Alzheimer's disease. Curr. Alzheimer Res., 2007, 
4, 159-164. 
[55]  Banks, W. A.; Jaspan, J. B.; Huang, W.; Kastin, A. J. Transport of 
insulin across the blood-brain barrier: saturability at euglycemic 
doses of insulin. Peptides, 1997, 18, 1423-1429. 
[56]  Pardridge, W. M.; Eisenberg, J.; Yang, J. Human blood-brain   
barrier insulin receptor. J. Neurochem., 1985, 44, 1771-1778. 
[57]  Frolich, L.; Blum-Degen, D.; Bernstein, H. G.; Engelsberger, S.; 
Humrich, J.; Laufer, S.; Muschner, D.; Thalheimer, A.; Turk, A.; 
Hoyer, S.; Zochling, R.; Boissl, K. W.; Jellinger, K.; Riederer, P. 
Brain insulin and insulin receptors in aging and sporadic Alz-
heimer's disease. J. Neural Transm., 1998, 105, 423-438. 
[58]  Frolich, L.; Blum-Degen, D.; Riederer, P.; Hoyer, S. A disturbance 
in the neuronal insulin receptor signal transduction in sporadic 
Alzheimer's disease. Ann. N. Y. Acad. Sci., 1999, 893, 290-293. 
[59]  Takahashi, M.; Yamada, T.; Tooyama, I.; Moroo, I.; Kimura,   
H.; Yamamoto, T.; Okada, H. Insulin receptor mRNA in the   
substantia nigra in Parkinson's disease. Neurosci. Lett., 1996, 204, 
201-204. 
[60]  Carro, E.; Torres-Aleman, I. The role of insulin and insulin-like 
growth factor I in the molecular and cellular mechanisms underly-
ing the pathology of Alzheimer's disease. Eur. J. Pharmacol., 2004, 
490, 127-133. 
[61]  Holscher, C.; van, A. L.; Sutherland, C. Anaesthesia generates 
neuronal insulin resistance by inducing hypothermia. BMC Neuro-
sci., 2008, 9, 100. 
[62]  Baura, G. D.; Foster, D. M.; Kaiyala, K.; Porte, D., Jr.; Kahn, S. E.; 
Schwartz, M. W. Insulin transport from plasma into the central 
nervous system is inhibited by dexamethasone in dogs. Diabetes, 
1996, 45, 86-90. 
[63]  Hartge, M. M.; Unger, T.; Kintscher, U. The endothelium and 
vascular inflammation in diabetes. Diab. Vasc. Dis. Res., 2007, 4, 
84-88. Consequences of Aberrant Insulin Regulation in the Brain  Current Neuropharmacology, 2011, Vol. 9, No. 4    703 
[64]  Kotzke, G.; Schutt, M.; Missler, U.; Moller, D. E.; Fehm, H. L.; 
Klein, H. H. Binding of human, porcine and bovine insulin to   
insulin receptors from human brain, muscle and adipocytes and   
to expressed recombinant alternatively spliced insulin receptor   
isoforms. Diabetologia, 1995, 38, 757-763. 
[65]  Roth, R. A.; Morgan, D. O.; Beaudoin, J.; Sara, V. Purification and 
characterization of the human brain insulin receptor. J. Biol. Chem., 
1986, 261, 3753-3757. 
[66]  Rees-Jones, R. W.; Hendricks, S. A.; Quarum, M.; Roth, J. The 
insulin receptor of rat brain is coupled to tyrosine kinase activity. J. 
Biol. Chem., 1984, 259, 3470-3474. 
[67]  de la Monte, S. M.; Wands, J. R. Review of insulin and insulin-like 
growth factor expression, signaling, and malfunction in the central 
nervous system: relevance to Alzheimer's disease. J. Alzheimers. 
Dis., 2005, 7, 45-61. 
[68]  Rivera, E. J.; Goldin, A.; Fulmer, N.; Tavares, R.; Wands, J. R.; de 
la Monte, S. M. Insulin and insulin-like growth factor expression 
and function deteriorate with progression of Alzheimer's disease: 
link to brain reductions in acetylcholine. J. Alzheimers Dis., 2005, 
8, 247-268. 
[69]  Neumann, K. F.; Rojo, L.; Navarrete, L. P.; Farias, G.; Reyes, P.; 
Maccioni, R. B. Insulin resistance and Alzheimer's disease: mo-
lecular links & clinical implications. Curr. Alzheimer Res., 2008, 5, 
438-447. 
[70]  den, H. T.; Vermeer, S. E.; van Dijk, E. J.; Prins, N. D.; Koudstaal, 
P. J.; Hofman, A.; Breteler, M. M. Type 2 diabetes and atrophy of 
medial temporal lobe structures on brain MRI. Diabetologia, 2003, 
46, 1604-1610. 
[71]  Nelson, P. T.; Smith, C. D.; Abner, E. A.; Schmitt, F. A.; Scheff, S. 
W.; Davis, G. J.; Keller, J. N.; Jicha, G. A.; Davis, D.; Wang-Xia, 
W.; Hartman, A.; Katz, D. G.; Markesbery, W. R. Human cerebral 
neuropathology of Type 2 diabetes mellitus. Biochim. Biophys. 
Acta, 2009, 1792, 454-469. 
[72]  Sugimoto, K.; Murakawa, Y.; Sima, A. A. Diabetic neuropathy--a 
continuing enigma. Diabetes Metab Res. Rev., 2000, 16, 408-433. 
[73]  Toth, C.; Martinez, J.; Zochodne, D. W. RAGE, diabetes, and the 
nervous system. Curr. Mol. Med., 2007, 7, 766-776. 
[74]  Beeri, M. S.; Schmeidler, J.; Silverman, J. M.; Gandy, S.; Wysocki, 
M.; Hannigan, C. M.; Purohit, D. P.; Lesser, G.; Grossman, H. T.; 
Haroutunian, V. Insulin in combination with other diabetes medica-
tion is associated with less Alzheimer neuropathology. Neurology, 
2008, 71, 750-757. 
[75]  Arvanitakis, Z.; Schneider, J. A.; Wilson, R. S.; Li, Y.; Arnold, S. 
E.; Wang, Z.; Bennett, D. A. Diabetes is related to cerebral infarc-
tion but not to AD pathology in older persons. Neurology, 2006, 
67, 1960-1965. 
[76]  Bertram, L.; Tanzi, R. E. Genome-wide association studies in Alz-
heimer's disease. Hum. Mol. Genet., 2009, 18, R137-R145. 
[77]  Beecham, G. W.; Martin, E. R.; Li, Y. J.; Slifer, M. A.; Gilbert, J. 
R.; Haines, J. L.; Pericak-Vance, M. A. Genome-wide association 
study implicates a chromosome 12 risk locus for late-onset Alz-
heimer disease. Am. J. Hum. Genet., 2009, 84, 35-43. 
[78]  Thal, D. R.; Griffin, W. S.; de Vos, R. A.; Ghebremedhin, E. Cere-
bral amyloid angiopathy and its relationship to Alzheimer's disease. 
Acta Neuropathol., 2008, 115, 599-609. 
[79]  Chalmers, K.; Wilcock, G. K.; Love, S. APOE epsilon 4 influences 
the pathological phenotype of Alzheimer's disease by favouring 
cerebrovascular over parenchymal accumulation of A beta protein. 
Neuropathol. Appl. Neurobiol., 2003, 29, 231-238. 
[80]  Profenno, L. A.; Faraone, S. V. Diabetes and overweight associate 
with non-APOE4 genotype in an Alzheimer's disease population. 
Am. J. Med. Genet. B Neuropsychiatr. Genet.,  2008,  147B,  
822-829. 
[81]  Messier, C. Diabetes, Alzheimer's disease and apolipoprotein   
genotype. Exp. Gerontol., 2003, 38, 941-946. 
[82]  Musicco, M.; Palmer, K.; Salamone, G.; Lupo, F.; Perri, R.; Mosti, 
S.; Spalletta, G.; di, I. F.; Pettenati, C.; Cravello, L.; Caltagirone, C. 
Predictors of progression of cognitive decline in Alzheimer's dis-
ease: the role of vascular and sociodemographic factors. J. Neurol., 
2009, 256, 1288-1295. 
[83]  Xu, W.; Qiu, C.; Winblad, B.; Fratiglioni, L. The effect of border-
line diabetes on the risk of dementia and Alzheimer's disease. Dia-
betes, 2007, 56, 211-216. 
[84]  Xu, W. L.; Qiu, C. X.; Wahlin, A.; Winblad, B.; Fratiglioni, L. 
Diabetes mellitus and risk of dementia in the Kungsholmen project: 
a 6-year follow-up study. Neurology, 2004, 63, 1181-1186. 
[85]  Irie, F.; Fitzpatrick, A. L.; Lopez, O. L.; Kuller, L. H.; Peila, R.; 
Newman, A. B.; Launer, L. J. Enhanced risk for Alzheimer disease 
in persons with type 2 diabetes and APOE epsilon4: the Cardiovas-
cular Health Study Cognition Study.  Arch. Neurol.,  2008,  65,  
89-93. 
[86]  Akomolafe, A.; Beiser, A.; Meigs, J. B.; Au, R.; Green, R. C.; 
Farrer, L. A.; Wolf, P. A.; Seshadri, S. Diabetes mellitus and risk  
of developing Alzheimer disease: results from the Framingham 
Study. Arch. Neurol., 2006, 63, 1551-1555. 
[87]  Luchsinger, J. A.; Tang, M. X.; Shea, S.; Mayeux, R. Hyperinsu-
linemia and risk of Alzheimer disease. Neurology, 2004, 63, 1187-
1192. 
[88]  Whitmer, R. A.; Karter, A. J.; Yaffe, K.; Quesenberry, C. P., Jr.; 
Selby, J. V. Hypoglycemic episodes and risk of dementia in   
older patients with type 2 diabetes mellitus. JAMA, 2009, 301, 
1565-1572. 
[89]  Ott, A.; Stolk, R. P.; van, H. F.; Pols, H. A.; Hofman, A.; Breteler, 
M. M. Diabetes mellitus and the risk of dementia: The Rotterdam 
Study. Neurology, 1999, 53, 1937-1942. 
[90]  Stolk, R. P.; Breteler, M. M.; Ott, A.; Pols, H. A.; Lamberts, S. W.; 
Grobbee, D. E.; Hofman, A. Insulin and cognitive function in an 
elderly population. The Rotterdam Study. Diabetes Care, 1997, 20, 
792-795. 
[91]  Biessels, G. J.; Staekenborg, S.; Brunner, E.; Brayne, C.; Scheltens, 
P. Risk of dementia in diabetes mellitus: a systematic review. Lan-
cet Neurol., 2006, 5, 64-74. 
[92]  Maher, P. A.; Schubert, D. R. Metabolic links between diabetes and 
Alzheimer's disease. Expert. Rev. Neurother., 2009, 9, 617-630. 
[93]  Taguchi, A. Vascular factors in diabetes and Alzheimer's disease. J. 
Alzheimers. Dis., 2009, 16, 859-864. 
[94]  in't Veld, B. A.; Ruitenberg, A.; Hofman, A.; Stricker, B. H.; Bre-
teler, M. M. Antihypertensive drugs and incidence of dementia: the 
Rotterdam Study. Neurobiol. Aging, 2001, 22, 407-412. 
[95]  Takeuchi, M.; Yamagishi, S. Possible involvement of advanced 
glycation end-products (AGEs) in the pathogenesis of Alzheimer's 
disease. Curr. Pharm. Des., 2008, 14, 973-978. 
[96]  Yan, S. D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slat-
tery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; 
Nawroth, P.; Stern, D.; Schmidt, A. M. RAGE and amyloid-beta 
peptide neurotoxicity in Alzheimer's disease. Nature,  1996,  382, 
685-691. 
[97]  Sugaya, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; 
Ando, A.; Inoko, H.; Ikemura, T. Three genes in the human MHC 
class III region near the junction with the class II: gene for receptor 
of advanced glycosylation end products, PBX2 homeobox gene and 
a notch homolog, human counterpart of mouse mammary tumor 
gene int-3. Genomics, 1994, 23, 408-419. 
[98]  Naka, Y.; Bucciarelli, L. G.; Wendt, T.; Lee, L. K.; Rong, L. L.; 
Ramasamy, R.; Yan, S. F.; Schmidt, A. M. RAGE axis: Animal 
models and novel insights into the vascular complications of diabe-
tes. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1342-1349. 
[99]  Bucciarelli, L. G.; Wendt, T.; Rong, L.; Lalla, E.; Hofmann, M. A.; 
Goova, M. T.; Taguchi, A.; Yan, S. F.; Yan, S. D.; Stern, D. M.; 
Schmidt, A. M. RAGE is a multiligand receptor of the immuno-
globulin superfamily: implications for homeostasis and chronic 
disease. Cell Mol. Life Sci., 2002, 59, 1117-1128. 
[100]  Lue, L. F.; Walker, D. G.; Jacobson, S.; Sabbagh, M. Receptor   
for advanced glycation end products: its role in Alzheimer's   
disease and other neurological diseases. Future. Neurol., 2009, 4, 
167-177. 
[101]  Lue, L. F.; Yan, S. D.; Stern, D. M.; Walker, D. G. Preventing 
activation of receptor for advanced glycation endproducts in Alz-
heimer's disease. Curr. Drug Targets. CNS. Neurol. Disord., 2005, 
4, 249-266. 
[102]  Yamagishi, S.; Nakamura, K.; Matsui, T.; Ueda, S.; Fukami, K.; 
Okuda, S. Agents that block advanced glycation end product 
(AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel 
therapeutic strategy for diabetic vascular complications. Expert. 
Opin. Investig. Drugs, 2008, 17, 983-996. 
[103]  Huijberts, M. S.; Schaper, N. C.; Schalkwijk, C. G. Advanced 
glycation end products and diabetic foot disease. Diabetes Metab 
Res. Rev., 2008, 24(Suppl 1), S19-S24. 
[104]  Jandeleit-Dahm, K.; Watson, A.; Soro-Paavonen, A. The 
AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin. Exp. 
Pharmacol. Physiol, 2008, 35, 329-334. 704    Current Neuropharmacology, 2011, Vol. 9, No. 4  Arab et al. 
[105]  Yamagishi, S.; Nakamura, K.; Imaizumi, T. Advanced glycation 
end products (AGEs) and diabetic vascular complications. Curr. 
Diabetes Rev., 2005, 1, 93-106. 
[106]  Yan, S. F.; Naka, Y.; Hudson, B. I.; Herold, K.; Yan, S. D.; 
Ramasamy, R.; Schmidt, A. M. The ligand/RAGE axis: lighting the 
fuse and igniting vascular stress. Curr. Atheroscler. Rep., 2006, 8, 
232-239. 
[107]  Hudson, B. I.; Wendt, T.; Bucciarelli, L. G.; Rong, L. L.; Naka, Y.; 
Yan, S. F.; Schmidt, A. M. Diabetic vascular disease: it's all the 
RAGE. Antioxid. Redox. Signal., 2005, 7, 1588-1600. 
[108]  Sato, T.; Shimogaito, N.; Wu, X.; Kikuchi, S.; Yamagishi, S.; 
Takeuchi, M. Toxic advanced glycation end products (TAGE) the-
ory in Alzheimer's disease. Am. J. Alzheimers. Dis. Other Demen., 
2006, 21, 197-208. 
[109]  Sato, T.; Iwaki, M.; Shimogaito, N.; Wu, X.; Yamagishi, S.; Take-
uchi, M. TAGE (toxic AGEs) theory in diabetic complications. 
Curr. Mol. Med., 2006, 6, 351-358. 
[110]  Takeuchi, M.; Yamagishi, S. Involvement of toxic AGEs (TAGE) 
in the pathogenesis of diabetic vascular complications and Alz-
heimer's disease. J. Alzheimers. Dis., 2009, 16, 845-858. 
[111]  Donahue, J. E.; Flaherty, S. L.; Johanson, C. E.; Duncan, J. A., III; 
Silverberg, G. D.; Miller, M. C.; Tavares, R.; Yang, W.; Wu, Q.; 
Sabo, E.; Hovanesian, V.; Stopa, E. G. RAGE, LRP-1, and amy-
loid-beta protein in Alzheimer's disease. Acta Neuropathol., 2006, 
112, 405-415. 
[112]  Jeynes, B.; Provias, J. Evidence for altered LRP/RAGE expression 
in Alzheimer lesion pathogenesis. Curr. Alzheimer Res., 2008, 5, 
432-437. 
[113]  Miller, M. C.; Tavares, R.; Johanson, C. E.; Hovanesian, V.; Dona-
hue, J. E.; Gonzalez, L.; Silverberg, G. D.; Stopa, E. G. Hippocam-
pal RAGE immunoreactivity in early and advanced Alzheimer's 
disease. Brain Res., 2008, 1230, 273-280. 
[114]  Sasaki, N.; Toki, S.; Chowei, H.; Saito, T.; Nakano, N.; Hayashi, 
Y.; Takeuchi, M.; Makita, Z. Immunohistochemical distribution of 
the receptor for advanced glycation end products in neurons and as-
trocytes in Alzheimer's disease. Brain Res., 2001, 888, 256-262. 
[115]  Deane, R.; Bell, R. D.; Sagare, A.; Zlokovic, B. V. Clearance of 
amyloid-beta peptide across the blood-brain barrier: implication for 
therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Tar-
gets., 2009, 8, 16-30. 
[116]  Giri, R.; Selvaraj, S.; Miller, C. A.; Hofman, F.; Yan, S. D.; Stern, 
D.; Zlokovic, B. V.; Kalra, V. K. Effect of endothelial cell polarity 
on beta-amyloid-induced migration of monocytes across normal 
and AD endothelium. Am. J. Physiol. Cell Physiol.,  2002,  283, 
C895-C904. 
[117]  Verdier, Y.; Zarandi, M.; Penke, B. Amyloid beta-peptide interac-
tions with neuronal and glial cell plasma membrane: binding sites 
and implications for Alzheimer's disease. J. Pept. Sci., 2004, 10, 
229-248. 
[118]  Verdier, Y.; Penke, B. Binding sites of amyloid beta-peptide in cell 
plasma membrane and implications for Alzheimer's disease. Curr. 
Protein Pept. Sci., 2004, 5, 19-31. 
[119]  Xie, L.; Helmerhorst, E.; Taddei, K.; Plewright, B.; Van, B.   
W.; Martins, R. Alzheimer's beta-amyloid peptides compete for   
insulin binding to the insulin receptor. J. Neurosci.,  2002,  22, 
RC221. 
[120]  Liao, F. F.; Xu, H. Insulin signaling in sporadic Alzheimer's dis-
ease. Sci. Signal., 2009, 2, e36. 
[121]  Zhao, W. Q.; De Felice, F. G.; Fernandez, S.; Chen, H.; Lambert, 
M. P.; Quon, M. J.; Krafft, G. A.; Klein, W. L. Amyloid beta oli-
gomers induce impairment of neuronal insulin receptors. FASEB J., 
2008, 22, 246-260. 
[122]  De Felice, F. G.; Vieira, M. N.; Bomfim, T. R.; Decker, H.; Ve-
lasco, P. T.; Lambert, M. P.; Viola, K. L.; Zhao, W. Q.; Ferreira, S. 
T.; Klein, W. L. Protection of synapses against Alzheimer's-linked 
toxins: insulin signaling prevents the pathogenic binding of Abeta 
oligomers. Proc. Natl. Acad. Sci. USA, 2009, 106, 1971-1976. 
[123]  Qiu, W. Q.; Walsh, D. M.; Ye, Z.; Vekrellis, K.; Zhang, J.;   
Podlisny, M. B.; Rosner, M. R.; Safavi, A.; Hersh, L. B.; Selkoe, 
D. J. Insulin-degrading enzyme regulates extracellular levels of 
amyloid beta-protein by degradation. J. Biol. Chem.,  1998,  273, 
32730-32738. 
[124]  McDermott, J. R.; Gibson, A. M. Degradation of Alzheimer's beta-
amyloid protein by human and rat brain peptidases: involvement of 
insulin-degrading enzyme. Neurochem. Res., 1997, 22, 49-56. 
[125]  Kurochkin, I. V.; Goto, S. Alzheimer's beta-amyloid peptide spe-
cifically interacts with and is degraded by insulin degrading en-
zyme. FEBS Lett., 1994, 345, 33-37. 
[126]  Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E. 
A.; Frosch, M. P.; Eckman, C. B.; Tanzi, R. E.; Selkoe, D. J.; 
Guenette, S. Insulin-degrading enzyme regulates the levels of   
insulin, amyloid beta-protein, and the beta-amyloid precursor   
protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA, 
2003, 100, 4162-4167. 
[127]  Vekrellis, K.; Ye, Z.; Qiu, W. Q.; Walsh, D.; Hartley, D.; 
Chesneau, V.; Rosner, M. R.; Selkoe, D. J. Neurons regulate ex-
tracellular levels of amyloid beta-protein via proteolysis by insulin-
degrading enzyme. J. Neurosci., 2000, 20, 1657-1665. 
[128]  Farris, W.; Mansourian, S.; Leissring, M. A.; Eckman, E. A.; 
Bertram, L.; Eckman, C. B.; Tanzi, R. E.; Selkoe, D. J. Partial loss-
of-function mutations in insulin-degrading enzyme that induce dia-
betes also impair degradation of amyloid beta-protein. Am. J. 
Pathol., 2004, 164, 1425-1434. 
[129]  Fernandez-Gamba, A.; Leal, M. C.; Morelli, L.; Castano, E. M. 
Insulin-degrading enzyme: structure-function relationship and its 
possible roles in health and disease. Curr. Pharm. Des., 2009, 15, 
3644-3655. 
[130]  Qiu, W. Q.; Folstein, M. F. Insulin, insulin-degrading enzyme and 
amyloid-beta peptide in Alzheimer's disease: review and hypothe-
sis. Neurobiol. Aging, 2006, 27, 190-198. 
[131]  Ho, L.; Qin, W.; Pompl, P. N.; Xiang, Z.; Wang, J.; Zhao, Z.; Peng, 
Y.; Cambareri, G.; Rocher, A.; Mobbs, C. V.; Hof, P. R.; Pasinetti, 
G. M. Diet-induced insulin resistance promotes amyloidosis in a 
transgenic mouse model of Alzheimer's disease. FASEB J., 2004, 
18, 902-904. 
[132]  Zhao, L.; Teter, B.; Morihara, T.; Lim, G. P.; Ambegaokar, S. S.; 
Ubeda, O. J.; Frautschy, S. A.; Cole, G. M. Insulin-degrading en-
zyme as a downstream target of insulin receptor signaling cascade: 
implications for Alzheimer's disease intervention. J. Neurosci., 
2004, 24, 11120-11126. 
[133]  Caccamo, A.; Oddo, S.; Sugarman, M. C.; Akbari, Y.; LaFerla, F. 
M. Age- and region-dependent alterations in Abeta-degrading en-
zymes: implications for Abeta-induced disorders. Neurobiol. Ag-
ing, 2005, 26, 645-654. 
[134]  Imrie, H.; Abbas, A.; Kearney, M. Insulin resistance, lipotoxicity 
and endothelial dysfunction. Biochim. Biophys. Acta, 2010, 1801, 
320-326. 
[135]  Belfiore, A.; Frasca, F.; Pandini, G.; Sciacca, L.; Vigneri, R. Insu-
lin receptor isoforms and insulin receptor/insulin-like growth factor 
receptor hybrids in physiology and disease. Endocr. Rev., 2009, 30, 
586-623. 
[136]  Staiger, H.; Machicao, F.; Fritsche, A.; Haring, H. U. Pathomecha-
nisms of type 2 diabetes genes. Endocr. Rev., 2009, 30, 557-585. 
[137]  Fernandez-Veledo, S.; Nieto-Vazquez, I.; Vila-Bedmar, R.; Garcia-
Guerra, L.; onso-Chamorro, M.; Lorenzo, M. Molecular mecha-
nisms involved in obesity-associated insulin resistance: therapeuti-
cal approach. Arch. Physiol. Biochem., 2009, 115, 227-239. 
[138]  Venables, M. C.; Jeukendrup, A. E. Physical inactivity and obesity: 
links with insulin resistance and type 2 diabetes mellitus. Diabetes 
Metab Res. Rev., 2009, 25(Suppl 1), S18-S23. 
[139]  McIntyre, R. S.; Vagic, D.; Swartz, S. A.; Soczynska, J. K.; 
Woldeyohannes, H. O.; Voruganti, L. P.; Konarski, J. Z. Insulin, 
insulin-like growth factors and incretins: neural homeostatic regu-
lators and treatment opportunities. CNS Drugs, 2008, 22, 443-453. 
[140]  Craft, S.; Peskind, E.; Schwartz, M. W.; Schellenberg, G. D.; 
Raskind, M.; Porte, D., Jr. Cerebrospinal fluid and plasma insulin 
levels in Alzheimer's disease: relationship to severity of dementia 
and apolipoprotein E genotype. Neurology, 1998, 50, 164-168. 
[141]  Watson, G. S.; Craft, S. Insulin resistance, inflammation, and cog-
nition in Alzheimer's Disease: lessons for multiple sclerosis. J. 
Neurol. Sci., 2006, 245, 21-33. 
[142]  Krogh-Madsen, R.; Plomgaard, P.; Keller, P.; Keller, C.; Pedersen, 
B. K. Insulin stimulates interleukin-6 and tumor necrosis factor-
alpha gene expression in human subcutaneous adipose tissue. Am. 
J. Physiol. Endocrinol. Metab., 2004, 286, E234-E238. 
[143]  Krogh-Madsen, R.; Moller, K.; Dela, F.; Kronborg, G.; Jauffred, 
S.; Pedersen, B. K. Effect of hyperglycemia and hyperinsulinemia 
on the response of IL-6, TNF-alpha, and FFAs to low-dose endo-
toxemia in humans. Am. J. Physiol. Endocrinol. Metab., 2004, 286, 
E766-E772. Consequences of Aberrant Insulin Regulation in the Brain  Current Neuropharmacology, 2011, Vol. 9, No. 4    705 
[144]  Soop, M.; Duxbury, H.; Agwunobi, A. O.; Gibson, J. M.; Hopkins, 
S. J.; Childs, C.; Cooper, R. G.; Maycock, P.; Little, R. A.; Carlson, 
G. L. Euglycemic hyperinsulinemia augments the cytokine and en-
docrine responses to endotoxin in humans. Am. J. Physiol. Endocrinol. 
Metab, 2002, 282, E1276-E1285. 
[145]  Magistretti, P. J.; Pellerin, L. Cellular mechanisms of brain   
energy metabolism. Relevance to functional brain imaging and   
to neurodegenerative disorders. Ann. N. Y. Acad. Sci., 1996, 777, 
380-387. 
[146]  Feil, D. G.; Pearman, A.; Victor, T.; Harwood, D.; Weinreb, J.; 
Kahle, K.; Unutzer, J. The role of cognitive impairment and care-
giver support in diabetes management of older outpatients. Int. J. 
Psychiatry Med., 2009, 39, 199-214. 
[147]  Sommerfield, A. J.; Deary, I. J.; Frier, B. M. Acute hyperglycemia 
alters mood state and impairs cognitive performance in people with 
type 2 diabetes. Diabetes Care, 2004, 27, 2335-2340. 
[148]  Yaffe, K.; Blackwell, T.; Whitmer, R. A.; Krueger, K.; Barrett, C. 
E. Glycosylated hemoglobin level and development of mild cogni-
tive impairment or dementia in older women. J. Nutr. Health Ag-
ing, 2006, 10, 293-295. 
[149]  Ryan, C. M.; Geckle, M. O. Circumscribed cognitive dysfunction 
in middle-aged adults with type 2 diabetes. Diabetes Care, 2000, 
23, 1486-1493. 
[150]  Szkudelski, T. The mechanism of alloxan and streptozotocin 
  action in B cells of the rat pancreas. Physiol. Res.,  2001,  50,  
537-546. 
[151]  Leal, M. C.; Dorfman, V. B.; Gamba, A. F.; Frangione, B.;   
Wisniewski, T.; Castano, E. M.; Sigurdsson, E. M.; Morelli, L. 
Plaque-associated overexpression of insulin-degrading enzyme in 
the cerebral cortex of aged transgenic tg2576 mice with Alzheimer 
pathology. J. Neuropathol. Exp. Neurol., 2006, 65, 976-987. 
[152]  Vepsalainen, S.; Hiltunen, M.; Helisalmi, S.; Wang, J.; van, G. T.; 
Tanila, H.; Soininen, H. Increased expression of Abeta degrading 
enzyme IDE in the cortex of transgenic mice with Alzheimer's dis-
ease-like neuropathology. Neurosci. Lett., 2008, 438, 216-220. 
[153]  Jolivalt, C. G.; Lee, C. A.; Beiswenger, K. K.; Smith, J. L.; Orlov, 
M.; Torrance, M. A.; Masliah, E. Defective insulin signaling path-
way and increased glycogen synthase kinase-3 activity in the brain 
of diabetic mice: parallels with Alzheimer's disease and correction 
by insulin. J. Neurosci. Res., 2008, 86, 3265-3274. 
[154]  Takeda, S.; Sato, N.; Uchio-Yamada, K.; Sawada, K.; Kunieda, T.; 
Takeuchi, D.; Kurinami, H.; Shinohara, M.; Rakugi, H.; Morishita, 
R. Diabetes-accelerated memory dysfunction via cerebrovascular 
inflammation and Abeta deposition in an Alzheimer mouse   
model with diabetes. Proc. Natl. Acad. Sci. USA,  2010,  107,  
7036-7041. 
[155]  Plaschke, K.; Kopitz, J.; Siegelin, M.; Schliebs, R.; Salkovic-
Petrisic, M.; Riederer, P.; Hoyer, S. Insulin-resistant brain state af-
ter intracerebroventricular streptozotocin injection exacerbates 
Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. 
J. Alzheimers Dis., 2010, 19, 691-704. 
[156]  Jolivalt, C. G.; Hurford, R.; Lee, C. A.; Dumaop, W.; Rockenstein, 
E.; Masliah, E. Type 1 diabetes exaggerates features of Alzheimer's 
disease in APP transgenic mice. Exp. Neurol., 2010, 223, 422-431. 
[157]  Ke, Y. D.; Delerue, F.; Gladbach, A.; Gotz, J.; Ittner, L. M.   
Experimental diabetes mellitus exacerbates tau pathology in a 
transgenic mouse model of Alzheimer's disease. PLoS One, 2009, 
4, e7917. 
[158]  Plastino, M.; Fava, A.; Pirritano, D.; Cotronei, P.; Sacco, N.; 
Sperli, T.; Spano, A.; Gallo, D.; Mungari, P.; Consoli, D.; Bosco, 
D. Effects of insulinic therapy on cognitive impairment in patients 
with Alzheimer disease and diabetes mellitus type-2. J. Neurol. 
Sci., 2010, 288, 112-116. 
[159]  Sanz, C.; Andrieu, S.; Sinclair, A.; Hanaire, H.; Vellas, B. Diabetes 
is associated with a slower rate of cognitive decline in Alzheimer 
disease. Neurology, 2009, 73, 1359-1366. 
[160]  Heneka, M. T.; Landreth, G. E. PPARs in the brain. Biochim. Bio-
phys. Acta, 2007, 1771, 1031-1045. 
[161]  Sundararajan, S.; Jiang, Q.; Heneka, M.; Landreth, G. PPAR-
gamma as a therapeutic target in central nervous system diseases. 
Neurochem. Int., 2006, 49, 136-144. 
[162]  Hanyu, H.; Sato, T.; Kiuchi, A.; Sakurai, H.; Iwamoto, T. Pioglita-
zone improved cognition in a pilot study on patients with Alz-
heimer's disease and mild cognitive impairment with diabetes mel-
litus. J. Am. Geriatr. Soc., 2009, 57, 177-179. 
[163]  Heneka, M. T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; 
Dewachter, I.; Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van, L. 
F.; Landreth, G. E. Acute treatment with the PPARgamma agonist 
pioglitazone and ibuprofen reduces glial inflammation and Abeta1-
42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453. 
[164]  Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Lecrux, C.; Fernan-
des, P.; Rosa-Neto, P.; Tong, X. K.; Hamel, E. Complete rescue of 
cerebrovascular function in aged Alzheimer's disease transgenic 
mice by antioxidants and pioglitazone, a peroxisome proliferator-
activated receptor gamma agonist. J.  Neurosci.,  2008, 28, 9287-
9296. 
[165]  Sato, T.; Hanyu, H.; Hirao, K.; Kanetaka, H.; Sakurai, H.;   
Iwamoto, T. Efficacy of PPAR-gamma agonist pioglitazone in mild 
Alzheimer disease. Neurobiol. Aging, 2009 [Epub ahead of print]. 
[166]  Pedersen, W. A.; McMillan, P. J.; Kulstad, J. J.; Leverenz, J. B.; 
Craft, S.; Haynatzki, G. R. Rosiglitazone attenuates learning and 
memory deficits in Tg2576 Alzheimer mice. Exp. Neurol., 2006, 
199, 265-273. 
[167]  Risner, M. E.; Saunders, A. M.; Altman, J. F.; Ormandy, G. C.; 
Craft, S.; Foley, I. M.; Zvartau-Hind, M. E.; Hosford, D. A.; Roses, 
A. D. Efficacy of rosiglitazone in a genetically defined population 
with mild-to-moderate Alzheimer's disease. Pharmacogenom. J., 
2006, 6, 246-254. 
[168]  Banks, W. A. The source of cerebral insulin. Eur. J. Pharmacol., 
2004, 490, 5-12. 
[169]  Kodl, C. T.; Seaquist, E. R. Cognitive dysfunction and diabetes 
mellitus. Endocr. Rev., 2008, 29, 494-511.  
 
 
Received: May 10, 2010  Revised: June 22, 2010  Accepted: July 21, 2010 
 